Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SKSQA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU-011
|
|||||
| Synonyms |
Belzupacap sarotalocan; AU011; AU 011
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Melanoma [ICD11:2C30]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.3-3.8
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
IRDye 700DX
|
Payload Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Sarotalocan
|
|||||
| TTD ID | ||||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.55% (Day 25) | |||
| Method Description |
C57BL/6-albino mice were subcutaneously inoculated with 5x105 MC38 on the right flank. Once the tumors had reached an average volume of approximately 125 mm3 as determined by measuring with a caliper, the mice were randomly divided into groups after which 100 g AU-011 in 100 uL was administered intravenously into the tail vein or intraperitoneally, or 30 g AU-011 in 30 L was administered intratumorally.
Click to Show/Hide
|
||||
| In Vivo Model | MC38 CDX model | ||||
| In Vitro Model | Mouse colon adenocarcinoma | MC-38 cells | CVCL_B288 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.